NASDAQ:VCNX Vaccinex (VCNX) Stock Price, News & Analysis $1.14 0.00 (0.00%) As of 10/9/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFDA EventsInsider TradesNews and TrendsSEC Filings About Vaccinex Stock (NASDAQ:VCNX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vaccinex alerts:Sign Up Key Stats Today's Range$1.14▼$1.1450-Day Range$0.72▼$1.2552-Week Range$0.31▼$1.50Volume131 shsAverage Volume2,962 shsMarket Capitalization$2.96 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Vaccinex, Inc. is a clinical-stage biotechnology company headquartered in Rochester, New York. The company develops antibody-based therapies for serious diseases, with a focus on conditions involving neurodegeneration, cancer and immune-system dysfunction. Vaccinex’s lead product candidate is pepinemab, also known as VX15/2503, a humanized monoclonal antibody designed to block Semaphorin 4D (SEMA4D). The company has evaluated pepinemab in clinical studies for Huntington’s disease and Alzheimer’s disease, as well as in oncology programs, including research investigating its potential use in combination with other cancer treatments. Vaccinex also maintains antibody-discovery and development capabilities intended to support the creation of additional therapeutic candidates and potential collaborations. The company’s programs are developed through clinical research conducted in the United States and in collaboration with academic and industry partners. Vaccinex was co-founded by Maurice Zauderer, Ph.D., who has served as its president and chief executive officer.AI Generated. May Contain Errors. Read More Receive VCNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VCNX Stock News HeadlinesSEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma StudyOctober 7, 2026 | globenewswire.comVaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026July 8, 2026 | globenewswire.comUrgent: Invest In ‘Elon’s iPhone’ Before July 22ndEarly Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider sources say Elon Musk is developing a breakthrough technology he describes as '10x bigger than the largest product in history.' Nvidia's CEO has called it 'the next biggest opportunity after AI,' with potential lifetime sales reaching $20 trillion. A launch date of July 22nd is on the radar for early investors positioning ahead of the announcement.October 12 at 1:00 AM | StocksToTrade (Ad)Vaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025April 29, 2026 | quiverquant.comQVaccinex Reports 2025 Annual Financial ResultsApril 29, 2026 | globenewswire.comVaccinex Inc.April 10, 2026 | barrons.comVaccinex announces $60M revenue sharing agreement with PDVDecember 23, 2025 | msn.comVaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s DiseaseDecember 23, 2025 | markets.businessinsider.comSee More Headlines VCNX Stock Analysis - Frequently Asked Questions How have VCNX shares performed this year? Vaccinex's stock was trading at $1.0755 at the beginning of the year. Since then, VCNX stock has increased by 6.0% and is now trading at $1.14. How were Vaccinex's earnings last quarter? Vaccinex, Inc. (NASDAQ:VCNX) released its quarterly earnings results on Monday, November, 8th. The company reported ($35.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($60.90) by $25.20. The firm had revenue of $0.05 million for the quarter. When did Vaccinex's stock split? Vaccinex's stock reverse split on the morning of Tuesday, February 20th 2024.The 1-14 reverse split was announced on Tuesday, February 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Vaccinex IPO? Vaccinex (VCNX) raised $45 million in an initial public offering on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager. How do I buy shares of Vaccinex? Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vaccinex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaccinex investors own include Pfizer (PFE), VBI Vaccines (VBIV), OPKO Health (OPK), Plug Power (PLUG), NIO (NIO) and SNDL (SNDL). Company Calendar Last Earnings11/08/2021Today10/11/2026Next Earnings (Estimated)11/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VCNX CIK1205922 Webwww.vaccinex.com Phone(585) 271-2700Fax585-271-2765Employees25Year Founded2001Profitability EPS (Trailing Twelve Months)($48.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.25 million Net MarginsN/A Pretax Margin-4,787.89% Return on EquityN/A Return on Assets-383.58% Debt Debt-to-Equity RatioN/A Current Ratio0.77 Quick Ratio0.77 Sales & Book Value Annual Sales$388 thousand Price / Sales7.64 Cash FlowN/A Price / Cash FlowN/A Book Value($2.59) per share Price / Book-0.44Miscellaneous Outstanding Shares2,600,000Free Float1,261,000Market Cap$2.96 million OptionableNo Data Beta1.10 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:VCNX) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredUrgent Attention to Executive Order #14363 (Buy This Stock Before Oct. 20thMarc Chaikin, a 60-year Wall Street veteran whose past clients include George Soros and Steve Cohen, built a s...Chaikin Analytics | SponsoredTomorrow, Wall Street goes home for two daysTomorrow at 4 PM Eastern, Wall Street closes for the weekend. Fund managers and billion-dollar accounts leave,...Tim Sykes | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredUrgent: Invest In ‘Elon’s iPhone’ Before July 22ndEarly Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...Crypto 101 Media | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccinex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccinex With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VCNX Stock Alerts